Immunoglobulin G1, Anti-(Human Cytotoxic T-Lymphocyte-Associated Antigen 4) (Human-Mus Musculus Monoclonal M3 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal M3 .Kappa.-Chain, Dimer
Melanoma
Explore 435 assets in Melanoma →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04700072CT.gov Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) | — | Completed | — | — | — |
NCT04305054CT.gov Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) | — | Completed | — | — | — |
NCT04305041CT.gov Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Human Cytotoxic T-Lymphocyte-Associated Antigen 4) (Human-Mus Musculus Monoclonal M3 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal M3 .Kappa.-Chain, Dimer (this asset) | Merck Sharp & Dohme LLC | P1/2 | CCC · 52 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Other indications for Immunoglobulin G1, Anti-(Human Cytotoxic T-Lymphocyte-Associated Antigen 4) (Human-Mus Musculus Monoclonal M3 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal M3 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P3 | BB · 64 |
| Hepatocellular Carcinoma | — | P2 | B · 57 |
| Non-Small Cell Lung Carcinoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Human Cytotoxic T-Lymphocyte-Associated Antigen 4) (Human-Mus Musculus Monoclonal M3 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal M3 .Kappa.-Chain, Dimer in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-cytotoxic-t-lymphocyte-associated-antigen-4-human-mus-musculus-monoclonal-m3-gamma1-chain-disulfide-with-human-mus-musculus-monoclonal-m3-kappa-chain-dimer-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →